Abbvie Biotherapeutics Inc.

United States of America

 
Total IP 75
Total IP Rank # 17,842
IP Activity Score 2.3/5.0    27
IP Activity Rank # 29,297
Parent Entity Abbvie Inc.

Patents

Trademarks

38 0
10 0
27 0
0
 
Last Patent 2024 - Anti-cd19 antibody drug conjugates
First Patent 1991 - Bispecific antibody heterodimers

Latest Inventions, Goods, Services

2023 Invention Anti-garp-tgf-β1/pd-1 combination therapy. The present disclosure provides methods of treating ca...
Invention Anti-cd19 antibody drug conjugates. The present disclosure provides anti-CD19 antibody drug conju...
Invention Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertini...
Invention Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin and osimertinib...
Invention Anti-cmet antibody drug conjugates and methods for their use. The present disclosure provides an...
2022 Invention Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin. The present d...
Invention Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin. The present di...
2021 Invention Anti-cd40 antibodies and their uses. The present disclosure provides novel anti-CD40 antibodies,...
Invention Anti-ox40 antibodies and their uses. The present disclosure provides novel anti-OX40 antibodies,...
Invention Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of can...
2020 Invention Anti-cd40 antibody and their uses. The present disclosure provides novel anti-CD40 antibodies, c...
Invention Anti-pd-1 antibodies and their uses. The present disclosure provides novel anti-PD-1 antibodies,...
Invention Dac hyp compositions and methods. The present disclosure relates to compositions of daclizumab s...
2019 Invention Anti-ox40 antibodies and their uses. The present disclosure provides novel anti-OX40 antibodies, ...
Invention Anti-pd-1 antibodies and their uses. The present disclosure provides novel anti-PD-1 antibodies, ...
Invention Anti-cd40 antibodies. The present disclosure provides novel anti-CD40 antibodies, compositions in...
Invention Therapeutic use of anti-cs1 antibodies. The present invention is directed to antagonists of CS1 ...
Invention Anti-cd40 antibody. The present disclosure provides novel anti-CD40 antibodies, compositions incl...
Invention Anti-cmet antibody drug conjugates and methods for their use. The present disclosure provides ant...
2018 Invention Anti-hulrrc15 antibody drug conjugates and methods for their use. The present disclosure provides...
Invention Anti-hulrrc15 antibody drug conjugates and methods for their use. The present disclosure provide...
Invention Vectors and host cells comprising a modified sv40 promoter for protein expression. The present d...
Invention Nucleic acid molecules encoding anti-cd40 antibodies. The present disclosure provides novel anti-...
Invention Bispecific binding proteins that bind cd40 and mesothelin. The present disclosure provides bispec...
Invention Fc variants. The present disclosure relates to polypeptide variants having modified Fc domains w...
2017 Invention Anti-cs1 antibodies and antibody drug conjugates. The present disclosure provides antibodies and ...
Invention Methods of treating progressive forms of multiple sclerosis. The present disclosure relates to m...
Invention Anti-pd-1(cd279) antibodies. The present disclosure provides novel anti-PD-1 antibodies, composit...
Invention Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing t...
Invention Anti-4-1bb antibodies and their uses. The present disclosure provides novel anti-4-1BB antibodies...